SavedAdd your journal

Journals / Güncel Retina Dergisi / 2018 / Cilt: 2 - Sayı: 2

Anti-VEGF Deficiency, Treatment Resistance, Pharmaceutical Changes and Combined Treatments in Diabetic Macular Edema

Diyabetik Makula Ödeminde Anti-VEGF’e Yanıtsızlık, Tedaviye Direnç, İlaç Değişimleri ve Kombine Tedaviler

Sema ORUÇ DÜNDAR
HARUN ÇAKMAK
Pages
165–169
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this review, unresponsiveness to anti-VEGF treatment, switch and combination therapy in DME are mentioned

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Diabetic retinopathy is the most important cause of blindness in developed countries today.
📊
Key Findings & Data:The most important cause of visual impairment is complications related to diabetic macular edema (DME) and proliferative retinopathy.
💡
Conclusion & Impact:In this review, unresponsiveness to anti-VEGF treatment, switch and combination therapy in DME are mentioned
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Diabetic retinopathy is the most important cause of blindness in developed countries today. The most important cause of visual impairment is complications related to diabetic macular edema (DME) and proliferative retinopathy. Intravitreal anti-VEGF agents are the first treatment option for central involvement diabetic macular edema (DME). Despite antiVEGF agents, some cases are refractory (persistent) to multiple anti-VEGF treatments. In this review, unresponsiveness to anti-VEGF treatment, switch and combination therapy in DME are mentioned

Özet

Diyabetik retinopati, günümüzde gelişmiş ülkelerde körlüğün en önemli nedenidir. Görme bozukluğunun en önemli nedeni diyabetik makula ödemi (DMÖ) ve proliferatif retinopatiye bağlı komplikasyonlardır. Santrali tutan DMÖ'de ilk tedavi seçeneği intravitreal anti-VEGF ajanlardır. Anti-VEGF ajanlara rağmen bazı olgular anti-VEGF ajanlara yanıtsız (persistan) kalmaktadır. Bu derlemede DMÖ'de anti-VEGF tedaviye yanıtsızlık, ilaç değişimleri ve kombine tedaviler ele alınmıştır

🔖

Cite This Article

DÜNDAR, S. O., ÇAKMAK, H. (2018). Anti-VEGF Deficiency, Treatment Resistance, Pharmaceutical Changes and Combined Treatments in Diabetic Macular Edema. Güncel Retina Dergisi, Cilt: 2 - Sayı: 2, 165–169. https://ajindex.com/articles/173573

References (14)

  1. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2010
  2. 33 Suppl 1:S62-9 2. American Diabetes Association. Foundations of care: Education, nutrition, physical activity, smoking cessation, psychosocial care, and immunization. Diabetes Care 2015, 38, S20–S30. 3. Alaboud AF, Tourkmani AM, Alharbi TJ, Alobikan AH, Abdelhay O, Al Batal SM, Alkashan HI, Mohammed UY. Microvascular and macrovascular complications of type 2 diabetic mellitus in Central, Kingdom of Saudi Arabia. Saudi Med J. 2016
  3. 37(12):1408-1411. 4. Ding J, Wong TY. Current epidemiology of diabetic retinopathy and diabetic macular edema. Curr Diab Rep. 2012
  4. 12(4):346-54. 5. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The Wisconsin epidemiologic study of diabetic retinopathy. IV. Diabetic macular edema. Ophthalmology. 1984
  5. 91(12):1464-74. 6. Bresnick GH. Diabetic macular edema. A review. Ophthalmology. 1986
  6. 93(7):989-97. 7. Bresnick GH. Diabetic maculopathy. A critical review highlighting diffuse macular edema. Ophthalmology. 1983
  7. 90(11):1301-17. 8. Cantrill HL. The diabetic retinopathy study and the early treatment diabetic retinopathy study. Int Ophthalmol Clin. 1984
  8. 24(4):13-29. 9. Schatz H, Yannuzzi LA, Gitter KA. Subretinal neovascularization following argon laser photocoagulation treatment for central serous chorioretinopathy: complication or misdiagnosis? Retina. 2012
  9. 32 Suppl 1:OP893-906. 10. Battaglia Parodi M, Bandello F. Is Laser Still Important in Diabetic Macular Edema as Primary or Deferral Therapy? Dev Ophthalmol. 2017
  10. Fazel F, Bagheri M, Golabchi K, Jahanbani Ardakani H. Comparison of subthreshold diode laser micropulse therapy versus conventional photocoagulation laser therapy as primary treatment of diabetic macular edema. J Curr Ophthalmol. 2016
  11. 28(4):206-211 12. Liew G, Lei Z, Tan G, Joachim N, Ho IV, Wong TY, Mitchell P, Gopinath B, Crossett B. Metabolomics of Diabetic Retinopathy. Curr Diab Rep. 2017
  12. 17(11):102 13. Hammes HP. Diabetic retinopathy: hyperglycaemia, oxidative stress and beyond. Diabetologia. 2017 Sep 24. doi: 10.1007/s00125-017-4435-8 14. Capitão M, Soares R. Angiogenesis and Inflammation Crosstalk in Diabetic Retinopathy. J Cell Biochem. 2016
  13. 117(11):2443-53. 15. Fogli S, Mogavero S, Egan CG, Del Re M, Danesi R. Pathophysiology and pharmacological targets of VEGF in diabetic macular edema. Pharmacol Res. 2016
  14. Virgili G, Parravano M, Evans JR, Gordon I, Lucenteforte E. Anti-vascu